Characteristic | Patients | |||
---|---|---|---|---|
All | LC (SCLC/NSCLC) | CRC | Other | |
(n = 30) | (n = 15, 5/10) | (n = 10) | (n = 5) | |
Initial concurrent anti-CCT regimen, n | ||||
 Intensive cytotoxic regimen and targeted agenta | 4 | 0 | 3 | 1 |
 Intensive cytotoxic regimenb | 19 | 10 (5/5) | 6 | 3 |
 Single targeted agentc | 2 | 2 (0/2) | 0 | 0 |
 Single cytotoxic agentd | 5 | 3 (0/3) | 1 | 1 |
Best response on anti-CCT after commencing concurrent chemotherapy, n | ||||
 CR | 1 | 0 | 1 | 0 |
 PR | 10 | 5 (4/1) | 3 | 2 |
 SD | 5 | 2 (0/2) | 3 | 0 |
 PD | 6 | 4 (0/4) | 2 | 0 |
 NE | 8 | 4 (1/3) | 1 | 3 |
ORR (%)e | 36.7 | 33.3 (80.0/10.0) | 40.0 | 40.0 |
Main anti-MTB chemotherapy, n | ||||
 2HREZ/7HRf | 15 | 8 (3/5) | 4 | 3 |
 6HRE/6HRg | 7 | 2 (0/2) | 4 | 1 |
 Levofloxacin-based | 8 | 5 (2/3) | 2 | 1 |
Duration of anti-MTB treatment (days), median (range) | 275.0 (72–637) | 274.0 (90–469) [274 (183–469)/255 (90–310)] | 259.0 (72–539) | 368.0 (273–637) |
Duration of concurrent chemotherapy (days), median (range) | 157.5 (13–408) | 117.0 (20–245) [93 (20–207)/121 (48–245)] | 168.5 (13–408) | 155.0 (51–376) |
MTB treatment outcomes, n (%) | All | LC | CRC | Other |
 Cured | 20 (66.7) | 10 (66.7) | 6 (60.0) | 4 (80.0) |
 Completed | 1 (3.3) | 0 | 1 (10.0) | 0 |
 Died | 9 (30) | 5 (33.3) | 3 (30.0) | 1 (20.0) |
 Failed | 0 | 0 | 0 | 0 |
 Not evaluated | 0 | 0 | 0 | 0 |
Success (%)h | 70.0 | 66.7 | 70.0 | 80.0 |